BMRN News

AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of DirectorsPR NewswireSAN RAFAEL, Calif., Sept...

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) on Wednesday announced positive Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, with the study meeting its primary endpoint and all secondary efficacy endpoints...

BioMarin Announces Positive Results of Phase 3 VOXZOGO (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence BioMarin Announces Positive Results of Phase 3 VOXZOGO (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence PR Newswire SAN RAFAEL, Calif., Sept. 9, 2026 Detailed...

Eric George Davis, EVP at BioMarin Pharmaceutical (NASDAQ:BMRN), reported an insider sell on September 3, according to a new SEC filing. What Happened: Davis opted to sell 17,557 shares of BioMarin Pharmaceutical,read more...

Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

BioMarin to Participate in Upcoming Investor Conferences BioMarin to Participate in Upcoming Investor Conferences PR Newswire SAN RAFAEL, Calif., Sept. 2, 2026 Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm ESTCantor Global Healthcare Conference 2026, September 10 at 10:20 am...